Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced third quarter and year-to-date operating results for 2013.  The company will host a conference call today to discuss financial results for the third quarter and year-to-date, and to provide an operational update on developments in the quarter.

"We are pleased to have made good progress toward our goals during the third quarter, moving forward in the development of our lead drug candidate, quizartinib.  We are excited about the upcoming events at ASH in December, where we will have the opportunity to present data from our most recent studies," said Michael Martino, Ambit's president and Chief Executive Officer. "As we head into the last quarter of 2013, we are looking forward to feedback from our upcoming FDA meeting in November and we will provide an update on our development and regulatory plans for quizartinib following that meeting.  Additionally, we remain on track to start our Phase 3 trial in early-2014, as previously guided."

Operational Update
The Company is pleased to announce the acceptance of four abstracts with preliminary data highlighting the Company's lead drug candidate, quizartinib.  Presentations of the final data and two additional posters will be presented during the ASH 55th Annual Meeting at the Ernest Morial Convention Center in New Orleans, LA on December 9, 2013.  Oral presentations include the following:

Results of Phase 2 Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML):  The purpo
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and Chief Executive Officer of Regulus, will present a ... Annual Healthcare Conference on Wednesday, March 4, 2015 ... at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 On behalf ... its affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript’s trade secrets, and that it improperly ... court entered an order denying motions for judgment notwithstanding ...
(Date:2/26/2015)... The Pittcon 2015 Exposition, which takes ... Morial Convention Center in New Orleans, Louisiana, will ... 2015) displaying products and services used by the ... The Exposition will offer the latest innovations in ... chemistry; drug discovery; nanotechnology; life sciences to include ...
(Date:2/26/2015)... NY (PRWEB) February 26, 2015 According ... Research “Agricultural Biotechnology Market For Transgenic Crops (Corn, Soybean, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... at USD 15,300 million in 2012 and is expected ... a CAGR of 9.5% from 2013 to 2019. ...
Breaking Biology Technology:Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Pittcon 2015 Announces Exposition Highlights 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3
... Although the <A , href="http://www.ambion.com/catalog/CatNum.php?1632"> ... were developed for labeling siRNA, they can , ... can be used for this application. See "<A , ... Introduced dsRNA in Cells " for experimintal data using dsRNA , ...
... , May 20, 2002, ... initially considered a bizarre phenomenon limited to petunias and a few ... topics in molecular biology , (<A , ... it has become clear that PTGS occurs in both plants , ...
... border=0 align="left" cellPadding=8 cellSpacing=1>, , ... Assays , Northern Blotting , ... , , ... Yes , Yes , Yes ...
Cached Biology Technology:Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 2Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 3Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 4RNA Interference and Gene Silencing: History and Overview 2RNA Interference and Gene Silencing: History and Overview 3RNA Interference and Gene Silencing: History and Overview 4RNA Interference and Gene Silencing: History and Overview 5RNA Interference and Gene Silencing: History and Overview 6RNA Interference and Gene Silencing: History and Overview 7RNA Interference and Gene Silencing: History and Overview 8RNA Interference and Gene Silencing: History and Overview 9RNA Interference and Gene Silencing: History and Overview 10RNA Interference and Gene Silencing: History and Overview 11RNA Interference and Gene Silencing: History and Overview 12RNA Interference and Gene Silencing: History and Overview 13RNA Interference and Gene Silencing: History and Overview 14RNA Interference and Gene Silencing: History and Overview 15RNA Interference and Gene Silencing: History and Overview 16RNA Interference and Gene Silencing: History and Overview 17RNA Interference and Gene Silencing: History and Overview 18RNA Interference and Gene Silencing: History and Overview 19RNA Interference and Gene Silencing: History and Overview 20RNA Interference and Gene Silencing: History and Overview 21RNA Interference and Gene Silencing: History and Overview 22RNA Interference and Gene Silencing: History and Overview 23RNA Interference and Gene Silencing: History and Overview 24Comparison of Different Methods of mRNA Quantitation 2Comparison of Different Methods of mRNA Quantitation 3
(Date:2/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces it ... Conference on January 29 th at 10:30 a.m. ... of NXT-ID will present and host a live Q&A ... and its full suite of biometric technologies. Investors can ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... the last decade, Asian farmers have cleared tens of thousands ... demand for palm oil, an increasingly popular food ingredient. Ancient ... cut down. As a result, the landscape of equatorial Asia ... and having a serious impact on the air as well ...
... UC Santa Barbara have made a significant discovery in understanding ... nature,s way of controlling whether these cells will renew, or ... or any other part of the human body. The study ... Cell . The scientists say the finding bodes ...
... flu interventions must be imposed quickly, if they are ... journal BMC Public Health have shown that ... within the home should reduce infection, but only if ... maintained for a relatively long period. Professor George ...
Cached Biology News:NASA study says climate adds fuel to Asian wildfire emissions 2NASA study says climate adds fuel to Asian wildfire emissions 3NASA study says climate adds fuel to Asian wildfire emissions 4Scientists shed light on inner workings of human embryonic stem cells 2Scientists shed light on inner workings of human embryonic stem cells 3Social separation stops flu spread, but must be started soon 2
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Normal human AB serum, pooled...
Recombinant Human HGF...
Recombinant Mouse MMP-9, CF...
Biology Products: